267 related articles for article (PubMed ID: 22689683)
1. The sorafenib plus nutlin-3 combination promotes synergistic cytotoxicity in acute myeloid leukemic cells irrespectively of FLT3 and p53 status.
Zauli G; Celeghini C; Melloni E; Voltan R; Ongari M; Tiribelli M; di Iasio MG; Lanza F; Secchiero P
Haematologica; 2012 Nov; 97(11):1722-30. PubMed ID: 22689683
[TBL] [Abstract][Full Text] [Related]
2. Synergistic cytotoxic activity of recombinant TRAIL plus the non-genotoxic activator of the p53 pathway nutlin-3 in acute myeloid leukemia cells.
Secchiero P; Zerbinati C; di Iasio MG; Melloni E; Tiribelli M; Grill V; Zauli G
Curr Drug Metab; 2007 May; 8(4):395-403. PubMed ID: 17504227
[TBL] [Abstract][Full Text] [Related]
3. Synergistic cytotoxicity of sorafenib with busulfan and nucleoside analogs in human FMS-like tyrosine kinase 3 internal tandem duplications-positive acute myeloid leukemia cells.
Song G; Valdez BC; Li Y; Liu Y; Champlin RE; Andersson BS
Biol Blood Marrow Transplant; 2014 Nov; 20(11):1687-95. PubMed ID: 25111583
[TBL] [Abstract][Full Text] [Related]
4. A novel combination therapy approach for the treatment of acute myeloid leukemia: the multi-kinase inhibitor sorafenib and the HDM2 inhibitor nutlin-3.
Weisberg E; Sattler M
Haematologica; 2012 Nov; 97(11):1620-1. PubMed ID: 23125243
[No Abstract] [Full Text] [Related]
5. The combination of Nutlin-3 and Tanshinone IIA promotes synergistic cytotoxicity in acute leukemic cells expressing wild-type p53 by co-regulating MDM2-P53 and the AKT/mTOR pathway.
Guo Y; Li Y; Wang FF; Xiang B; Huang XO; Ma HB; Gong YP
Int J Biochem Cell Biol; 2019 Jan; 106():8-20. PubMed ID: 30389549
[TBL] [Abstract][Full Text] [Related]
6. Upregulation of SOCS-1 by Nutlin-3 in acute myeloid leukemia cells but not in primary normal cells.
Tisato V; Norcio A; Celeghini C; Milani D; Gonelli A; Secchiero P
Clinics (Sao Paulo); 2014 Jan; 69(1):68-74. PubMed ID: 24473562
[TBL] [Abstract][Full Text] [Related]
7. Reversal of acquired drug resistance in FLT3-mutated acute myeloid leukemia cells via distinct drug combination strategies.
Zhang W; Gao C; Konopleva M; Chen Y; Jacamo RO; Borthakur G; Cortes JE; Ravandi F; Ramachandran A; Andreeff M
Clin Cancer Res; 2014 May; 20(9):2363-74. PubMed ID: 24619500
[TBL] [Abstract][Full Text] [Related]
8. Selective induction of TP53I3/p53-inducible gene 3 (PIG3) in myeloid leukemic cells, but not in normal cells, by Nutlin-3.
Voltan R; Secchiero P; Corallini F; Zauli G
Mol Carcinog; 2014 Jun; 53(6):498-504. PubMed ID: 23192887
[TBL] [Abstract][Full Text] [Related]
9. Dasatinib plus Nutlin-3 shows synergistic antileukemic activity in both p53 wild-type and p53 mutated B chronic lymphocytic leukemias by inhibiting the Akt pathway.
Zauli G; Voltan R; Bosco R; Melloni E; Marmiroli S; Rigolin GM; Cuneo A; Secchiero P
Clin Cancer Res; 2011 Feb; 17(4):762-70. PubMed ID: 21106726
[TBL] [Abstract][Full Text] [Related]
10. Phosphoproteome Analysis Reveals Differential Mode of Action of Sorafenib in Wildtype and Mutated FLT3 Acute Myeloid Leukemia (AML) Cells.
Roolf C; Dybowski N; Sekora A; Mueller S; Knuebel G; Tebbe A; Murua Escobar H; Godl K; Junghanss C; Schaab C
Mol Cell Proteomics; 2017 Jul; 16(7):1365-1376. PubMed ID: 28450419
[TBL] [Abstract][Full Text] [Related]
11. Molecular mechanisms of nutlin-3 involve acetylation of p53, histones and heat shock proteins in acute myeloid leukemia.
Haaland I; Opsahl JA; Berven FS; Reikvam H; Fredly HK; Haugse R; Thiede B; McCormack E; Lain S; Bruserud O; Gjertsen BT
Mol Cancer; 2014 May; 13():116. PubMed ID: 24885082
[TBL] [Abstract][Full Text] [Related]
12. Metformin synergistically sensitizes FLT3-ITD-positive acute myeloid leukemia to sorafenib by promoting mTOR-mediated apoptosis and autophagy.
Wang F; Liu Z; Zeng J; Zhu H; Li J; Cheng X; Jiang T; Zhang L; Zhang C; Chen T; Liu T; Jia Y
Leuk Res; 2015 Dec; 39(12):1421-7. PubMed ID: 26505133
[TBL] [Abstract][Full Text] [Related]
13. 1,25-dihydroxyvitamin D3 enhances the apoptotic activity of MDM2 antagonist nutlin-3a in acute myeloid leukemia cells expressing wild-type p53.
Thompson T; Andreeff M; Studzinski GP; Vassilev LT
Mol Cancer Ther; 2010 May; 9(5):1158-68. PubMed ID: 20406950
[TBL] [Abstract][Full Text] [Related]
14. Nutlin-3 up-regulates the expression of Notch1 in both myeloid and lymphoid leukemic cells, as part of a negative feedback antiapoptotic mechanism.
Secchiero P; Melloni E; di Iasio MG; Tiribelli M; Rimondi E; Corallini F; Gattei V; Zauli G
Blood; 2009 Apr; 113(18):4300-8. PubMed ID: 19190243
[TBL] [Abstract][Full Text] [Related]
15. Selective FLT3 inhibitor FI-700 neutralizes Mcl-1 and enhances p53-mediated apoptosis in AML cells with activating mutations of FLT3 through Mcl-1/Noxa axis.
Kojima K; Konopleva M; Tsao T; Andreeff M; Ishida H; Shiotsu Y; Jin L; Tabe Y; Nakakuma H
Leukemia; 2010 Jan; 24(1):33-43. PubMed ID: 19946262
[TBL] [Abstract][Full Text] [Related]
16. Nutlin-3 enhances sorafenib efficacy in renal cell carcinoma.
Vatsyayan R; Singhal J; Nagaprashantha LD; Awasthi S; Singhal SS
Mol Carcinog; 2013 Jan; 52(1):39-48. PubMed ID: 22006587
[TBL] [Abstract][Full Text] [Related]
17. The MDM-2 antagonist nutlin-3 promotes the maturation of acute myeloid leukemic blasts.
Secchiero P; Zerbinati C; Melloni E; Milani D; Campioni D; Fadda R; Tiribelli M; Zauli G
Neoplasia; 2007 Oct; 9(10):853-61. PubMed ID: 17971905
[TBL] [Abstract][Full Text] [Related]
18. Pre-apoptotic response to therapeutic DNA damage involves protein modulation of Mcl-1, Hdm2 and Flt3 in acute myeloid leukemia cells.
Wergeland L; Sjøholt G; Haaland I; Hovland R; Bruserud Ø; Gjertsen BT
Mol Cancer; 2007 May; 6():33. PubMed ID: 17498302
[TBL] [Abstract][Full Text] [Related]
19. A novel tescalcin-sodium/hydrogen exchange axis underlying sorafenib resistance in FLT3-ITD+ AML.
Man CH; Lam SS; Sun MK; Chow HC; Gill H; Kwong YL; Leung AY
Blood; 2014 Apr; 123(16):2530-9. PubMed ID: 24608976
[TBL] [Abstract][Full Text] [Related]
20. Integrin alphavbeta3 enhances β-catenin signaling in acute myeloid leukemia harboring Fms-like tyrosine kinase-3 internal tandem duplication mutations: implications for microenvironment influence on sorafenib sensitivity.
Yi H; Zeng D; Shen Z; Liao J; Wang X; Liu Y; Zhang X; Kong P
Oncotarget; 2016 Jun; 7(26):40387-40397. PubMed ID: 27248172
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
